Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V

Sagawa, Tamotsu, Hirakawa, Masahiro, Nagashima, Hiroyuki, Fujikawa, Koshi · 2026 · Journal of Gastrointestinal Cancer

Abstract

Purpose KRAS mutations are present in approximately 40-45% of colorectal cancers (CRC), but currently approved KRAS-directed therapies address only the small G12C subset. G12D and G12V account for a much larger proportion of KRAS-mutant CRC and remain major unmet therapeutic targets. This review summarizes emerging strategies for non-G12C KRAS-mutant CRC. Methods Current preclinical, translational, and early clinical evidence was narratively synthesized, focusing on allele-specific G12D and G12V inhibitors, pan-RAS approaches, upstream SOS1/SHP2 co-targeting, anti-EGFR combinations, immune-based strategies, and tissue and circulating tumor DNA profiling. Results The development of MRTX1133, zoldonrasib (RMC-9805), VS-7375, RMC-5127, and daraxonrasib (RMC-6236) demonstrates that direct targeting of previously undruggable KRAS alleles is becoming clinically feasible. In CRC, however, EGFR-mediated feedback reactivation of wild-type RAS remains a central resistance mechanism, making anti-EGFR combination strategies particularly important.Tissue and circulating tumor DNA profiling may support patient selection, monitoring of clonal evolution, and characterization of acquired resistance. Conclusion The non-G12C KRAS era is beginning, but durable benefit in CRC will likely require rational combinations tailored to allele, lineage, and resistance biology.

Overview

Integrity signals

Registry

Crossref · 10.1007/s12029-026-01579-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 36 references

Research works printed but not linked: 2

  1. Kwan AK, Piha-Paul SA, Cleary JM, et al. HRS-4642, a KRAS G12D inhibitor: initial results from a phase 1 study in advanced solid tumors. Ann Oncol. 2024;35(Suppl 2):S638–9. [ESMO 2024, Abstract 599O].
  2. Rosen LS, Brana I, Calles A, et al. A phase Ib study of RMC-4630, a potent SHP2 inhibitor, combined with adagrasib in patients with KRAS-mutant solid tumors. J Clin Oncol. 2023;41(Suppl 16):3005. [ASCO 2023 abstract].

Cited by

See all 1

Metadata

Authors
Sagawa, T., Hirakawa, M., Nagashima, H., & Fujikawa, K.
Affiliations
  • Sapporo National Hospital (JP)
  • Sapporo Medical University (JP)
Corresponding author
Sagawa, Tamotsu
Venue
Journal of Gastrointestinal Cancer
Published
2026-09-01
Volume
57
Issue
1
ISSN
  • 1941-6628 (ISSN-L)
  • 1941-6636
OpenAlex
W7204956421
Cited by
1
References
36
Citations by year
2026: 1
FWCI
0.92
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Gastrointestinal Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS mutation, colorectal cancer, KRAS inhibitors, MRTX1133, daraxonrasib, pan-RAS inhibitors, SOS1, SHP2, immune checkpoint inhibitors, circulating tumor DNA, clonal evolution, acquired resistance, patient selection
MeSH terms
Animals, Antineoplastic Agents, Humans, Mutation, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V. https://app.cochat.ai/papers/10.1007/s12029-026-01579-8
The paper
Sagawa, T., Hirakawa, M., Nagashima, H., & Fujikawa, K. (2026). Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-026-01579-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.